Milestone Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MIST and other ETFs, options, and stocks.

About MIST

Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. Its lead product candidate etripamil, is a novel, potent and short-acting calcium channel blocker that is designed as a rapid-onset nasal spray to be self-administered by patients. 

CEO
Joseph G. Oliveto
CEOJoseph G. Oliveto
Employees
38
Employees38
Headquarters
Montréal, Québec
HeadquartersMontréal, Québec
Founded
2003
Founded2003
Employees
38
Employees38

MIST Key Statistics

Market cap
182.97M
Market cap182.97M
Price-Earnings ratio
-2.39
Price-Earnings ratio-2.39
Dividend yield
Dividend yield
Average volume
1.75M
Average volume1.75M
High today
$1.61
High today$1.61
Low today
$1.53
Low today$1.53
Open price
$1.58
Open price$1.58
Volume
487.80K
Volume487.80K
52 Week high
$3.06
52 Week high$3.06
52 Week low
$1.00
52 Week low$1.00

Stock Snapshot

The current Milestone Pharmaceuticals(MIST) stock price is $1.56, with a market capitalization of 182.97M. The stock trades at a price-to-earnings (P/E) ratio of -2.39.

As of 2026-05-15, Milestone Pharmaceuticals(MIST) stock has fluctuated between $1.53 and $1.61. The current price stands at $1.56, placing the stock +1.6% above today's low and -3.4% off the high.

Milestone Pharmaceuticals(MIST) shares are trading with a volume of 487.8K, against a daily average of 1.75M.

During the past year, Milestone Pharmaceuticals(MIST) stock moved between $1.00 at its lowest and $3.06 at its peak.

During the past year, Milestone Pharmaceuticals(MIST) stock moved between $1.00 at its lowest and $3.06 at its peak.

MIST News

TipRanks 2d
Milestone Pharmaceuticals reports Q1 EPS (20c), consensus 19c

Reports Q1 revenue $238,000, consensus $37.64M. “We’re excited to report on our first quarter of sales for CARDAMYST for paroxysmal supraventricular tachycardia...

Nasdaq 2d
Milestone Pharmaceuticals Reports Q1 Loss, Lags Revenue Estimates

Milestone Pharmaceuticals (MIST) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of $0.06. This compares to a loss of $0.31...

Milestone Pharmaceuticals Reports Q1 Loss, Lags Revenue Estimates

Analyst ratings

83%

of 6 ratings
Buy
83.3%
Hold
16.7%
Sell
0%

People also own

Based on the portfolios of people who own MIST. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.